Glaukos Corporation (NYSE: GKOS) — A Category-Creating Glaucoma Franchise Priced for the Ramp to Never Stumble

Independent Equity Research Analyst desk: Ophthalmic Medical Technology & Pharmaceuticals Report date: July 18, 2026 · Price (2026-07-17 close): $156.83 · Market cap: ~$9.15B · Enterprise value: ~$8.95B (net cash) Fiscal year: December · CIK: 0001192448 · Coverage: Fresh initiation

⚡ Claude’s Take

This block is the author’s own independent opinion and is provided for general information only — it is not investment advice. The analysis that follows (sections 1–15) takes no position and carries no price target; a single opinion appears only in this clearly-labeled block.

Verdict: HOLD / AVOID-here — a genuinely good business at a price that already assumes it wins. Not a short. Accumulate-on-weakness only in the ~$100–120 zone (roughly 11–12x forward sales / a re-test of the reimbursement-scare lows). Conviction: medium.

Glaukos is the rare small-cap medtech that has actually invented a new category. iDose TR — a travoprost implant placed inside the eye that quietly lowers glaucoma pressure for years and is reimbursed at ~$14.7k per implant on a permanent J-code — is a legitimately differentiated, high-gross-margin, recurring (~3-year re-dosing) procedural-pharma annuity, and it is single-handedly driving the company from $315M (2023) to a guided $620–635M (2026). That is real, it is organic, and it is high quality. The problem is not the business; it is the price and the shape of the bet. At ~16x trailing / ~14x forward EV/sales — the 89th percentile of Glaukos’s own decade of valuation and the richest EV/sales in a peer set where even Intuitive and Edwards only earn a “fair-to-full” HOLD — the stock has fully re-embedded the bull case after doubling off its late-2025 lows. You are paying a proven-compounder multiple for an still-GAAP-lossmaking company (FY25 net loss −$188M, negative free cash flow every year of its public life, opex ~95% of revenue) whose entire per-share thesis rests on two unproven conversions: (1) iDose/Epioxa keep ramping with reimbursement intact, and (2) a cost base that eats ~two dollars of overhead-and-R&D per dollar of gross profit finally operating-levers into EW/ISRG-class margins. Both are plausible. Neither is in hand.

The framing is a momentum melt-up, not a falling knife — and I want to be precise about that because it cuts against buying here. FactorsToday has Glaukos +58% over the trailing year (Sharpe ~1.06), +166% annualized over three months, sitting 2.7% off its relative-strength peak; the factor-similar cohort is high-growth momentum (Zscaler, the med-device growth ETFs), not distressed value. The tape is a one-way street up, powered by four consecutive analyst price-target hikes to $150–180 and back-to-back guidance raises. That is exactly the regime in which single-category medtech gets overpriced, and exactly the setup that halved this same stock in 2025 (−55% from $161 to $75) the last time reimbursement fear met a full multiple. Insiders are not arguing with my caution: zero open-market purchases in 24 months — including straight through that 55% drawdown — against steady (planned) selling, with the CEO the largest monetizer. What flips me bullish: durable evidence that iDose net price and MAC professional fees hold and operating margin crosses into sustained positive FCF — at which point the multiple is defensible. What flips me bearish: a CMS/MAC professional-fee cut or ASP erosion on iDose, or an Epioxa payer-coverage stall — any of which, at this multiple, re-runs the 2025 movie. Tag: “The best story in ophthalmology, already told back to me at the ask.”

📈 Stock Price Action — Five-Year Event Map

Over the trailing ~60 months Glaukos round-tripped from a $34.86 low (May 2022) to a $161.22 all-time high (Jan 23, 2025), then collapsed ~55% to a $74.67 52-week low (Oct 24, 2025), and has since nearly doubled back to $156.83 (2026-07-17) — sitting just ~2.7% below its all-time high, at the very top of a $74.67–$156.84 52-week range. The stock is effectively back where it peaked, but the fuel has changed: the 2024 run was reimbursement optimism; the 2026 recovery is iDose/Epioxa launch execution and serial guidance raises.

Price moves are FACT (AZI 5-year CSV); attributed drivers are INTERPRETATION cross-referenced to 8-K/earnings dates. No target, no recommendation — the opportunity judgment lives in Claude’s Take above.

Cycle narrative. (1) The 2021–22 collapse was macro-and-reimbursement (CMS stent-fee pressure + a rising-rate de-rating of profitless growth), not company execution. (2) The iDose TR approval (Dec 13, 2023) was the cleanest catalyst in the company’s history — a ~30% two-day pop that anchored the 2024 bull run. (3) 2024 melted up ~75% on reimbursement optimism and the controlled iDose launch, to the $161 ATH. (4)–(5) The 2025 unwind began with a −20% single-day drop on the Feb 2025 guidance print as iDose reimbursement-transition risk surfaced, then macro dragged the stock to $74.67. (6) The Epioxa approval (Oct 2025) was a non-event — fully priced. (7) The $115.5M impairment was looked through as the expected Photrexa→Epioxa succession. (8) The doubling since late 2025 is a launch-execution/momentum re-rate that has restored the stock to ~2.7% off its high.

1. Executive Summary

Glaukos is a $9.2B-market-cap ophthalmic medical-technology-and-pharmaceutical company built around three franchises: glaucoma (the iStent family of micro-invasive glaucoma surgery, or “MIGS,” stents plus the breakthrough iDose TR procedural-pharmaceutical implant), corneal health (Photrexa cross-linking for keratoconus, now succeeded by the internally-developed Epioxa), and an early-stage retina/pipeline portfolio. Glaucoma is ~83% of revenue and the US is ~74%.

The investment reality is a barbell. On one arm is a genuinely category-creating, high-quality growth engine — iDose TR did ~$54M in Q1’26 alone (a >$216M annualized run-rate from a standing start in 2024), carries a permanent J-code (not an expiring pass-through), is reimbursed at ~$14.7k per implant, re-doses roughly every three years, and runs at ~84% adjusted gross margin. iDose has driven company revenue from $314.7M (FY23) → $383.5M (FY24) → $507.4M (FY25, +32%), with Q1’26 up 41% and FY26 guidance raised to $620–635M. On the other arm is a flat-to-declining legacy iStent business (hit by Nov-2024 Medicare LCDs restricting stacked MIGS), a just-launched Epioxa still building payer coverage, a still-unprofitable P&L (FY25 GAAP net loss −$187.7M; negative free cash flow every year; opex ~95% of revenue), a history of dilution-financed growth (share count +30% in five years; SBC 12.5% of revenue; a ~$500M all-stock Avedro acquisition just partially written off via a $112.9M Photrexa impairment), and insiders who have not bought a single share on the open market in 24 months.

The moat is real but narrow: first-mover intangibles/IP in iDose and a narrow FDA-approved-CXL monopoly in corneal — not the scale, network effects, or deep switching costs of a wide-moat compounder. Glaukos is the subscale challenger to Alcon (~55–60% of glaucoma-surgery-device value), and its most valuable asset (iDose economics) is ultimately reimbursement-derived and therefore revocable — the exact fault line that halved the stock in 2025.

At ~16x trailing / ~14x forward EV/sales — the 89th percentile of its own history and the richest in its medtech peer set — the market is underwriting years of uninterrupted iDose + Epioxa execution and an unproven margin inflection to compounder-class profitability. The business is strengthening; the per-share case rests on conversions not yet in hand. This memo takes no position on price; it lays out what must be true for the bulls and the bears, and where the thesis breaks.

2. Business Overview

What Glaukos does. Glaukos designs, develops, and commercializes ophthalmic therapies across three franchises, reported as a single operating segment but managed as three commercial lines:

1. Glaucoma (~83% of FY25 revenue). Two distinct sub-businesses:
   • iStent MIGS devices — trabecular micro-bypass stents (iStent inject W for mild-to-moderate open-angle glaucoma implanted adjunctively during cataract surgery; iStent infinite as a standalone for refractory glaucoma). These are low-price (~$1,000/procedure) devices sold buy-and-bill; this is the historical core and it is now flat-to-declining.
   • iDose TR — a first-of-its-kind intracameral procedural pharmaceutical: a titanium implant, placed inside the anterior chamber of the eye, that elutes travoprost (a prostaglandin analog) continuously for an extended period, targeting the chronic non-adherence problem of daily glaucoma eye-drops. FDA-approved December 2023; the growth engine.
2. Corneal Health (~17% of FY25 revenue). Bio-activated corneal cross-linking (CXL) for progressive keratoconus — riboflavin drug formulations (Photrexa) activated by the KXL UV device (the iLink platform), acquired in the 2019 Avedro deal. In FY26 this franchise is transitioning from the legacy “epi-off” Photrexa to the internally-developed, next-generation “epi-on” Epioxa (FDA-approved October 2025, launched H1 2026), which does not require removal of the corneal epithelium.
3. Retina & pipeline (pre-revenue). Sustained-release intravitreal implants, the iLution transdermal platform (GLK-321 for Demodex blepharitis, Phase 2), a keratoconus screening device, and iDose adjacencies (TREX/TRIO next-gen, re-administration).

Revenue by franchise and geography (FACT, FY25 10-K disaggregation, filed 2026-02-23):

The economic engines are radically different, and that is the whole story. The iStent stents are a classic, low-price device business. iDose TR is a procedural-pharmaceutical — a fundamentally superior economic model. It carries a permanent HCPCS J-code (J7355, effective 7/1/2024) — this is critical: it is not the transitional/temporary pass-through that the launch-era bears feared would expire. iDose is billed at 75 units per implant at ASP+6% (less sequestration), acquired via buy-and-bill or specialty pharmacy, at a 2026 Medicare payment limit of ~$195.72/unit → ~$14,679 per implant (FACT, CMS/fee-schedule data, accessed Jul 2026). The procedure itself is billed through CPT 0660T/0661T, mapped to facility APC 5492, with a separate professional fee set by each of the seven Medicare Administrative Contractors (MACs). iDose carries broad national commercial and Medicare Advantage coverage.

Recurring vs. non-recurring. Nothing is subscription-recurring, but iDose’s ~3-year re-dosing cadence (a January 2026 sNDA formally approved re-administration) and CXL’s procedure-driven demand give the franchise a “procedure-annuity” quality materially better than one-and-done device sales. This is the structural upgrade the bull case is built on: Glaukos is trying to convert a mediocre one-time-device business into a recurring interventional-pharma business.

Verdict. Glaukos is a hybrid device/pharma company mid-transformation. The reported single segment masks three very different businesses: a declining legacy device line, a rapidly scaling procedural-pharma franchise with genuinely attractive unit economics, and an FDA-monopoly corneal line in the middle of a product swap. The quality of the overall business is rising precisely because the mix is shifting toward iDose.

3. Industry Dynamics

MIGS / glaucoma-surgery devices — structurally mediocre. The MIGS device market is modest and maturing (~$540M in 2023, ~5% CAGR per Grand View, accessed Jul 2026); the broader glaucoma-surgery-device market (~$1.8B, 2025) is dominated by Alcon (~55–60% value share across its franchise, including the Hydrus Microstent acquired via Ivantis). This is not, on its own, an attractive market: mid-single-digit growth, a dominant incumbent, and — critically — active reimbursement compression. In November 2024, five of seven MACs finalized Local Coverage Determinations confirming non-coverage of combined/“stacked” MIGS procedures performed with cataract surgery, disrupting stent ordering and driving the legacy iStent business flat-to-down. Device reimbursement is a headwind, not a tailwind.

Glaucoma drug market — large and underpenetrated by interventional therapy. Millions of open-angle-glaucoma and ocular-hypertension patients are treated with daily topical drops that suffer notorious non-adherence (patients simply stop instilling drops). This is the enormous chronic pool that iDose targets by moving therapy from “patient remembers eye-drops” to “physician places a multi-year implant.” Interventional penetration is tiny today, which is why iDose’s runway can be long even though the device market beneath it grows slowly. The most important structural insight on Glaukos is that iDose creates a new procedural-pharma category sitting on top of a slow device market — the company is attempting to escape a mediocre industry into a better one it defines.

Keratoconus / corneal cross-linking — small, underpenetrated, TAM-expanding via epi-on. US keratoconus prevalence is ~54.5/100,000; the CXL device market is only ~$290–420M globally. Epioxa’s epithelium-on (incision-free) approach removes the debridement step that deterred adoption in younger/earlier-stage patients — expanding the addressable population — but off a small base. Management’s stated ambition is to return the franchise to peak-Photrexa volumes (~18,000–19,000 eyes/year) by the end of the decade, with a larger ultimate TAM.

Reimbursement/regulatory landscape is the industry’s defining feature. Every dollar of Glaukos economics flows through CMS/MAC coding, coverage, and payment decisions: MIGS device coverage (compressed in 2024), iDose’s J-code and MAC professional fees (the swing factor), and Epioxa’s coverage build-out (temporary Category III CPT 0402T today, permanent J-code J2789 effective 7/1/2026, plus commercial-payer policy). The self-pay-adjacent / premium-tier dynamic familiar from the broader ophthalmic-surgical market (where refractive/premium-cataract procedures let patients pay out of pocket, insulating manufacturers from government price pressure) applies only partially here — iDose and Epioxa are primarily reimbursed, not cash-pay — which is why reimbursement durability is the pivotal variable rather than a secondary one.

Verdict: a structurally mixed-to-below-average industry, rescued by category creation and a narrow FDA monopoly. The device markets are slow-growing, reimbursement-pressured, and Alcon-dominated. What makes Glaukos interesting is not the industry it sits in but the new interventional-pharma category it is building (iDose) and its regulatory near-monopoly in FDA-approved CXL (Photrexa → Epioxa). Structurally good sub-niches carved out of a structurally average industry — which is a very different (and more fragile) proposition than owning a wide-moat position in a good industry.

4. Competitive Position

Naming the moat (Greenwald taxonomy): primarily intangibles/IP + first-mover advantage, plus a narrow regulatory monopoly in corneal. NOT scale, NOT network effects, and only weak switching costs.

• Intangibles / IP (real but time-limited). Glaukos holds >500 issued/pending patents plus in-licenses (Ripple, Attillaps, iVeena, Stuart). iDose TR is genuinely first-of-its-kind — a multi-year intracameral travoprost implant with a secured, permanent reimbursement pathway. That combination of first-mover clinical data + coding + commercial infrastructure is a real advantage. But patents expire, and multiple players (Alcon among them) are developing sustained-release glaucoma pharma. This is a head-start, not a fortress.
• Switching costs (weak). Surgeon training, buy-and-bill workflow familiarity, and clinical comfort create some stickiness, but a surgeon can switch products procedure-to-procedure. This is habit and relationship, not lock-in — closer to a pharma-detailing dynamic than to an installed-base platform.
• Scale (adverse). Glaukos is subscale versus Alcon, which has ~55–60% of glaucoma-surgery-device value, a full ophthalmic salesforce, and deep surgeon relationships across cataract/refractive/retina. Glaukos is the challenger; it does not enjoy the cost or distribution advantages of the scale leader.
• Network effects: none.
• Regulatory monopoly (corneal). Photrexa/iLink is (was) the only FDA-approved bio-activated CXL therapy in the US — a genuine but narrow moat, now being handed to the equally-narrow Epioxa monopoly.

Head-to-head.

• iStent MIGS vs. Alcon (Hydrus Microstent), Sight Sciences (OMNI/SION), AbbVie/Allergan (XEN gel stent), New World Medical, Nova Eye. This is a crowded, commoditizing, reimbursement-restricted category. The legacy iStent business is flat-to-declining; there is no durable moat here beyond installed surgeon relationships. The market-share-stability test fails on the legacy line — it is losing ground and being reimbursement-squeezed.
• iDose TR vs. AbbVie Durysta (bimatoprost implant). Durysta is a single-use, ~4-month biodegradable implant with a checkered commercial record; iDose’s multi-year duration and interventional positioning are clearly differentiated. iDose is the class leader today — but the lead is a head-start against a field (Alcon and others in sustained-release) that will arrive.
• Corneal — Photrexa/Epioxa near-monopoly. The only FDA-approved CXL, but threatened by (a) off-label/compounded epi-on protocols (cheaper, physician-preferred workflow) and (b) Epion Therapeutics developing a competitive CXL. Epioxa both defends this position (an FDA-approved epi-on answer to compounding) and cannibalizes Photrexa — margin-accretive and TAM-expanding, but the near-term net corneal growth is muted by the swap (hence high-single-digit franchise guidance despite a major launch).

Pressure test — is there a financial outcome that deteriorates without the moat? Yes, sharply — and that is the tell of how narrow it is. iDose’s entire economics are reimbursement-derived: the ~$14.7k/implant is ASP+6% plus a MAC-set professional fee. If CMS/MACs compress the professional fee, or ASP erodes as volume and competition build, the unit economics — and the thesis — degrade quickly. The November-2024 LCD MIGS restriction is live proof that a single reimbursement decision can flatten a franchise’s growth overnight. So the “moat” is best described as first-mover + a secured-but-revocable reimbursement pathway + a narrow FDA CXL monopoly — durable enough for a multi-year runway, but not a wide, self-reinforcing moat. A true moat would show up as pricing power that survives competition and reimbursement scrutiny; Glaukos’s does not yet clear that bar.

Verdict: narrow, category-specific advantage. Real in iDose (first-mover + reimbursement + data) and in FDA-approved CXL (regulatory monopoly); weak-to-absent in legacy MIGS stents. Durable for now, but IP- and reimbursement-dependent, and challenger-scale against Alcon — not structurally impregnable.

5. Growth History and Forward Opportunities

Historical (organic in the growth franchises; corneal was acquired via Avedro in 2019).

• Total revenue $314.7M → $383.5M → $507.4M (FY23→24→25): +22% then +32%.
• US glaucoma +50% in FY25 ($199.6M → $298.6M) — essentially all iDose TR, partially offset by a single-digit decline in legacy stents (the LCD headwind). This is the crux: iDose is carrying the entire company’s growth while the historical core is flat-to-shrinking.
• International glaucoma +18% (FY25), broad-based volume (France, UK, Japan) plus modest FX; iStent infinite launched in the EU following MDR certification late 2025.
• Corneal +8% (FY25), mostly US Photrexa price/new accounts net of Medicaid rebates.

Current trajectory (FACT, Q1’26 call, 2026-04-29). Q1’26 revenue $150.6M (+41% reported, +39% constant-currency); management raised FY26 guidance to $620–635M (from $600–620M) — implying ~22–25% full-year growth. Franchise composition of the guide:

• US glaucoma ~low-30s% growth — the iDose sequential ramp is the driver, with non-iDose stents assumed flat (“until proven otherwise”). iDose was ~$54M in Q1’26 alone.
• International glaucoma low-double-digit (high-single-digit ex-FX), with flagged competitive product-trialing headwinds in major international markets partly offset by iStent infinite in Europe.
• Corneal high-single-digit — the Photrexa→Epioxa transition plus the temporary→permanent J-code (J2789, 7/1/2026) creates Q2–Q3 volatility, with a stronger 2H exit “as Epioxa pulls through.”

Margin quality is genuinely improving. Adjusted gross margin was ~84% in Q1’26 (+120bps YoY), with FY26 guidance of 84–86% and further accretion flagged into 2027 as Epioxa (higher-margin than Photrexa) mixes in. Note the wide GAAP-vs-adjusted gap (Section 6 bridges it): reported GAAP gross margin was ~56% in FY25 versus ~75% in FY24, depressed by the one-time Photrexa impairment and by acquired-intangible amortization — the underlying margin is genuinely 84%+.

Pipeline optionality (mostly free options, mostly unproven): iDose TREX (2nd-gen extended release), iDose TRIO (Phase 3 completed), iStent infinite for mild-to-moderate (pivotal), PRESERFLO MicroShunt (US IDE, licensed from Santen), iLution/GLK-321 for Demodex blepharitis (Phase 2 enrollment completed 2026-06-25), a keratoconus screening device (launch late 2026), iLution myopia, and retinal intravitreal assets — 5 therapeutic platforms / 13 disclosed programs.

High- vs. low-quality growth. The growth is high quality where it matters: iDose is organic, high-price, category-creating procedural pharma with recurring re-dosing and 84%+ gross margins, expanding an underpenetrated interventional market. Epioxa is TAM-expanding and margin-accretive. The lower-quality / at-risk pieces are (a) legacy iStent (flat-to-declining, reimbursement-pressured — a melting sub-franchise), and (b) a working-capital flag: the 10-K notes extended payment terms offered during the iDose launch, so channel-load/DSO risk deserves monitoring (receivables have grown faster than revenue — see Section 6). And all of it is being funded ahead of profits.

Verdict: high-quality, category-creating growth — but most of the reasonable base case is already in the price. A credible multi-year path is roughly $625M (FY26) → high-$700s/low-$800sM (FY27) → ~$1B (FY28–29) if iDose keeps ramping and Epioxa scales, plausibly driving GAAP profitability as the 84–86% gross margin flows through a stabilizing cost base. But at ~14x forward EV/sales on a still-lossmaking company, the upside case requires iDose to keep compounding and reimbursement to hold and margins to inflect — three things at once, against a multiple with little margin for error.

6. Financial Quality

Revenue growth and composition — the best part of the story. Five-year revenue: FY21 $294.0M → FY22 $282.9M → FY23 $314.7M → FY24 $383.5M → FY25 $507.4M, with FY25 +32% and Q1’26 +41%. The composition is improving (mix-shift to high-margin iDose), and the sequential 2025 cadence was clean acceleration: Q1 $106.7M → Q2 $124.1M → Q3 $133.5M → Q4 $143.1M → Q1’26 $150.6M. TTM revenue is ~$551M. This is unambiguously a high-growth top line.

Gross margin — underlying ~78–84%, with a one-time GAAP distortion to normalize. ROIC/EDGAR reported gross margin collapsed to 55.7% in FY25 from ~75.5% (FY24) and ~76% (FY23). This is not operational deterioration: it reflects a $115.5M non-cash charge in Q4’25 — specifically a $112.9M write-off of the Photrexa developed-technology intangible plus a $2.6M Photrexa inventory write-down — run through cost of sales (10-K MD&A/Notes). Normalizing that out, and per management’s adjusted disclosure, the underlying gross margin is ~78% GAAP-clean / ~84% adjusted (Q1’26 GAAP GM was back to 77.9%). Acquired-intangible amortization from Avedro (~$26.8M/yr developed-tech + ~$14.1M/yr customer relationships) remains a structural COGS drag on the reported number. QoE conclusion: value Glaukos on the ~78–84% underlying margin, not the FY25 optical 55.7%.

Operating losses — large but narrowing as a percentage of revenue. The core problem is cost intensity: FY25 total opex was ~95% of revenue — SG&A $331.7M (65.4% of revenue) and R&D $150.6M (29.7%). The multi-year trend is slow deleveraging off a brutal base (SG&A/revenue 71%→68%→65% across FY23→25; R&D/revenue 44%→36%→30%). GAAP operating loss was −$199.6M in FY25 (−$84M ex-impairment); Q1’26 operating loss narrowed to just −$19.9M (−13.2% margin) vs. −$20.7M (−19.4%) a year earlier. The direction is right, but Glaukos still spends roughly two dollars of overhead-and-development for every dollar of gross profit while it launches iDose and Epioxa simultaneously.

Bottom line and cash flow — still red, still burning, but improving. FY25 GAAP net loss was −$187.7M (EPS −$3.28 on 57.2M shares**)**; Q1’26 net loss −$19.8M (EPS −$0.34). Free cash flow has been negative every year of Glaukos’s public life — FY25 −$39.1M, FY24 −$67.6M, FY23 −$78.0M — though the burn is moderating as revenue scales (FY25 CFO was only −$14.8M). Management’s explicit near-term objective is operating leverage and cash-flow breakeven. Until that arrives, the company is not self-funding.

Balance sheet — a genuine strength. As of Q1’26: cash + short-term investments $276.7M ($104.2M cash + $172.4M investments) against $103.1M of “debt” that is actually a finance/build-to-suit lease on the Aliso Viejo HQ — i.e., essentially net cash (~$174M). The $287.5M of 2.75% convertible notes due 2027 were fully retired in 2024 (see Section 7), removing the overhang. Total equity is $671M — but note that reflects $1.62B of paid-in capital against a −$953M accumulated deficit, and ~$200M of intangibles + $67M goodwill sit inside the asset base (tangible book is far lower). Current ratio ~5.4x; liquidity is not a concern. Glaukos can fund its path to breakeven from the balance sheet without raising equity — an important de-risking of the bear case.

Dilution and SBC — the recurring drag. Shares outstanding grew from 44.5M (FY20) to ~58.1M (Feb 2026) — roughly +30% in five years (the 2024 convert exchange added 4.25M; the rest is options/RSU/ESPP issuance). SBC was $63.2M in FY25 = 12.5% of revenue — and because FCF is negative, SBC is not a benign “non-cash add-back” here; it is effectively part of how the company is financed. Any normalized-earnings framework must charge SBC as a real cost.

ROIC/ROE not meaningful. With persistent GAAP losses, return metrics are negative (ROA −13% to −20%) and uninformative; there is no positive ROIC to test against cost of capital yet. This is a pre-profitability compounder — the return question is entirely about future economics, not current ones.

Verdict: do economics improve with scale? Yes — but they have not yet crossed the line. The gross-margin structure (~84% adjusted) is excellent and improving; operating leverage is visibly appearing (Q1’26 operating margin −13% vs. −19% a year ago); the balance sheet is net cash; and the burn is shrinking. But Glaukos remains GAAP-unprofitable and FCF-negative, with a 12.5%-of-revenue SBC bill and a +30% five-year share count. The financial quality is improving toward — but does not yet demonstrate — the compounder economics its valuation assumes.

7. Capital Allocation

The core pattern: a launch-stage growth machine financed by dilution, never by internally-generated cash. Glaukos has never generated positive free cash flow, so every dollar of M&A, R&D, and launch spending is ultimately financed by equity (SBC + convert-to-equity) and, historically, debt. There is no dividend and no buyback authorization (10-K: “never declared or paid any cash dividends”; no repurchase program). Glaukos is a net issuer in every period — the opposite end of the capital-allocation spectrum from a company returning cash.

M&A and the impairment — a genuine mark against the marquee deal. The $115.5M FY25 impairment is a $112.9M write-off of the Photrexa developed-technology intangible + a $2.6M inventory write-down. Photrexa is the CXL drug Glaukos acquired in the ~$500M all-stock Avedro deal (2019, ~11M shares). The write-off was triggered because Glaukos is superseding Photrexa (“epi-off”) with its own internally-developed Epioxa (“epi-on,” approved Oct 2025), rendering the acquired intangible no longer fully recoverable.

• Interpretation: This is a real negative on the Avedro acquisition — the company is writing off the carrying value of the very product it paid ~$500M to acquire, seven years later. It is not a clean value-destruction story (the acquired KXL device, CXL market position, and regulatory/commercial infrastructure are being succeeded by a better in-house product, not abandoned), but the Avedro purchase still amortizes ~$41M/yr of intangibles into COGS and has now been partially impaired. Net return on the ~$500M Avedro deal, after impairment and given Epioxa’s still-unproven launch economics, is at best mediocre — and an open question.
• Smaller deals are cheap and reasonable: Mobius Therapeutics/Mitosol (~$12.4M cash + royalties, 2025), DOSE Medical, Intratus/iLution, plus license deals (Santen PRESERFLO, Attillaps, iVeena, Ripple, Stuart). These are sensible pipeline/tuck-in options. Glaukos also bought a $16.6M Aliso Viejo building (2025) and carries the ~$103M finance lease on its HQ.

Convertible-note cleanup (dilutive but overhang-clearing). Glaukos issued $287.5M of 2.75% convertible senior notes due 2027 in 2020 and cleaned them up entirely in 2024: exchanged $230.0M principal for 4,253,423 shares (June 2024), redeemed the remaining $57.5M for cash (Dec 2024), and unwound 50% of the capped-call hedge for $53.2M cash. The overhang and interest are gone; the ~4.25M shares of dilution are permanent. On balance a reasonable resolution of a legacy instrument, executed while the stock was high.

R&D / SG&A intensity — extreme, the direct cause of the losses. As above, opex ran ~95% of revenue in FY25. This is defensible if it is genuine growth investment that operating-levers down (the bull view, supported by the Q1’26 margin improvement) and indefensible if it is a structurally bloated cost base (the bear view). The evidence is trending toward the former but is not yet conclusive.

Insider behavior — a soft-negative tell. From a full parse of 126 Form 4s over the trailing 24 months:

• Zero open-market purchases (code P) in 24 months — including straight through the ~55% drawdown from $161 to the $74.67 low. No insider bought a single share at any price.
• 44 sales (435,040 shares), all 10b5-1-planned — programmatic diversification, the benign reading, not a discretionary rush for the exits. But combined with zero buying, the net posture is distribution.
• CEO Thomas Burns is by far the largest monetizer (exercised 441,000 options, sold 275,000 shares under 10b5-1 — roughly $24–26M at Jan 2026 prices — plus gifts/grants). CFO Alex Thurman has minimal activity (newer, still building a position). Directors show the routine exercise-and-immediately-sell pattern.
• Net signal: neutral-to-mildly-negative. All selling is planned, but there is no offsetting conviction buying at any price, and the CEO has been a consistent large seller. Insiders are harvesting equity comp, not accumulating.

Verdict: below-average capital allocation — dilution-financed “growth at any cost,” not demonstrated per-share value creation. Management has assembled a genuinely credible ophthalmic pipeline, but has done so via continuous equity issuance, a richly-priced all-stock Avedro deal it has now partially written off, chronic 12%+ SBC, a +30% share count, and no return of capital. The bull rebuttal — that the pipeline is finally inflecting revenue (+32%) and the losses are self-inflicted launch spend that will operate-lever down — is plausible and is starting to show in the numbers, but it is unproven. On the evidence to date, business progress has not yet translated into shareholder (per-share) value.

8. Changes and Headwinds — Last Two Years

Product / regulatory (net positive):

• iDose TR FDA approval (Dec 2023) and controlled launch (Feb 2024) — the defining positive event.
• Epioxa FDA approval (Oct 20, 2025), launched H1 2026 — an FDA-approved epi-on CXL that defends the corneal franchise against compounding and expands the TAM.
• iDose re-administration sNDA approved (Jan 2026) — formalizes the ~3-year re-dosing annuity, materially important to the long-term model.
• Pipeline advanced across five platforms (iDose TREX/TRIO, iStent infinite mild-to-moderate, PRESERFLO, iLution/GLK-321 Phase 2, KC screening device).

Reimbursement (mixed — the swing factor):

• iDose procedural codes (0660T/0661T) reassigned to APC 5492 retroactive to Jan 2024 (a positive resolution); iDose now on a permanent J-code (J7355). But iDose reimbursement-transition risk was the trigger for the Feb 2025 selloff, and MAC professional fees are still being finalized (5 of 7 MACs now stable).
• Legacy iStent hit by the Nov-2024 MAC LCDs restricting stacked/combined MIGS — a live example of reimbursement flattening a franchise.
• Epioxa coverage build-out is the key open item — temporary Category III CPT 0402T today, permanent J-code J2789 effective 7/1/2026, commercial-payer policies still being written (>100M covered commercial lives established, 4 of 5 largest payers engaged).

Balance sheet / accounting:

• Convertible notes fully retired (2024) — overhang gone, ~4.25M shares of dilution booked; net-cash position maintained.
• $115.5M Photrexa impairment (Q4’25) — an accounting acknowledgment that the Avedro-acquired product is being superseded.

Leadership / governance: A co-CEO structure emerged — founder Thomas Burns as Chairman & CEO, Joseph Gilliam as President & CEO — worth monitoring as a succession signal. CFO Alex Thurman is relatively new. Heavy but planned insider selling; no material litigation surfaced in the 8-K sweep.

Verdict: net modestly thesis-strengthening on the product/commercial axis, offset by unresolved reimbursement execution and continued dilution. The two years delivered exactly what the pipeline promised — two major approvals driving +32% revenue and a convert cleanup — but also crystallized the Avedro impairment and left the equity story hostage to (a) Epioxa’s payer-coverage build and (b) whether the ~95%-of-revenue cost base finally operating-levers. The business is stronger; the per-share case still rests on unproven margin conversion.

9. Risk Analysis

Downside characterization. The realistic downside is not a wipeout — Glaukos is net cash with a real, growing, high-margin revenue base — it is a multiple de-rating. A stock at ~14x forward sales that decelerates or takes a reimbursement hit can lose 30–50% while the business is still fine, exactly as it did in 2025. The asymmetry a buyer at $157 faces is a business with genuine catastrophe-resistance wrapped in a valuation with genuine drawdown risk.

10. Valuation Discussion (Embedded Expectations)

No price target, no recommendation — this section frames what the market is underwriting.

Where the multiple sits. At $156.83, market cap is ~$9.15B and enterprise value ~$8.95B (net cash). Against TTM revenue of ~$551M, that is ~16.2x EV/TTM sales; against the FY26 guide midpoint ($627.5M), ~14.3x EV/forward sales. On the company’s own history, the AZI valuation-index places P/S at the 89th percentile and P/B at the 90th percentile of the past decade — i.e., near its richest-ever valuation. (P/E is not meaningful — GAAP losses — so P/S and P/B are the right own-history lenses, and both scream “expensive vs. itself.”)

Peer context (comparable public companies). Glaukos is the most expensive name in its peer set on EV/sales — and the only GAAP-unprofitable one:

Glaukos is priced like an early-innings Edwards or Intuitive — single-category, high-growth, moat-y — but without their proven margin structure. High-teens EV/sales is only defensible if 30%+ growth and a credible path to EW/ISRG-class ~25% FCF margins both hold. The peer set’s clearest lesson is de-rate risk: BSX went ~30x→~14x and ALGN ~50–60x GAAP→~13.6x adjusted when growth decelerated. Anchoring GKOS scenario multiples to where deceleration re-rated these peers (not to today’s melt-up multiple) is the disciplined approach.

Scenario analysis (illustrative; assumptions explicit, no target implied).

• Bear (~$95–120 equivalent). iDose adoption plateaus and/or a MAC professional-fee cut or ASP erosion hits; legacy stents keep melting; revenue stalls near ~$750M by 2028; margin inflection is slow. The market re-rates toward ~8–10x forward sales (BSX/decelerated-peer territory) → EV ~$6.5–7.5B → roughly $95–120/share. This is the 2025-movie-rerun scenario, and the stock has already demonstrated it can trade there.
• Base (~$150–175 equivalent, ≈ today). iDose keeps ramping, Epioxa scales through its coverage build, revenue reaches ~$1.0–1.1B by 2028–29, GAAP profitability arrives with a ~15–20% FCF margin. A ~10–12x forward-sales / ~30–35x forward-FCF multiple → EV ~$9–10.5B → roughly $150–180/share. The current price sits inside the base case — i.e., the market is paying for the base case in full today.
• Bull (~$220–260 equivalent). iDose category-defines and the re-dosing annuity compounds; iDose TREX/TRIO extend the franchise; Epioxa hits and exceeds peak-Photrexa; pipeline options (retina, iLution) begin to contribute; revenue exceeds ~$1.4B by 2029–30 at 25%+ FCF margins, and the market sustains a premium growth multiple → EV ~$13–15B → roughly $220–260/share.

What must be true for today’s price? The ~14x forward-sales multiple embeds, at minimum: (1) iDose continues to compound at a high rate for several years with reimbursement (J-code + MAC fees + ASP) essentially intact; (2) Epioxa converts its coverage build into a franchise that at least offsets Photrexa cannibalization and grows; (3) the ~95%-of-revenue cost base operating-levers into sustained positive FCF within a couple of years; and (4) legacy iStent’s decline stays gradual, not disorderly. That is a coherent, internally-consistent bull case — but it is four things going right at once, priced at a near-record multiple, in a business whose single most valuable asset is reimbursement-derived and therefore revocable.

What is the market plausibly getting right vs. wrong? Right: iDose is genuinely differentiated, the growth is real and organic, the balance sheet is net cash, and the margin trajectory is improving. Potentially wrong: (a) treating a reimbursement-derived advantage as if it were a durable moat with pricing power; (b) extrapolating the launch-phase ramp linearly through competitive entry and ASP normalization; and © awarding compounder-class multiples before the company has demonstrated a single year of positive free cash flow.

11. Variant Perception

Consensus view. Sell-side is uniformly bullish — four price-target hikes in June–July 2026 alone (Citi $175, Truist $180, Stifel $175, Piper $165, plus a fresh HC Wainwright Buy initiation), all clustering above the current price. The consensus narrative: iDose is a category-defining, multi-year procedural-pharma growth story with reimbursement de-risked (permanent J-code), Epioxa is a free option on a larger corneal TAM, and margins inflect as launches scale. The tape agrees — a momentum melt-up back to within 2.7% of the all-time high.

Strongest bull case. Glaukos has invented a durable new category. iDose converts the enormous, non-adherent topical-glaucoma population into a recurring, high-margin, physician-administered annuity that re-doses every ~3 years — a razor/blade-like installed base of patients. With a permanent J-code removing the cliff, national coverage, an 84%+ gross margin, a net-cash balance sheet, and a deep pipeline (TREX/TRIO, iStent infinite mild-moderate, retina, iLution), revenue compounds past $1.4B with EW/ISRG-class margins by decade-end, and today’s multiple proves cheap in hindsight. The 2025 drawdown was the buying opportunity; the recovery validates it.

Strongest bear case. Glaukos is a still-lossmaking, dilution-financed challenger in a slow, Alcon-dominated device market, whose single valuable asset (iDose economics) is a reimbursement-derived, revocable pathway — not a moat. The multiple (~14x forward sales, 89th-percentile own-history) has fully re-embedded a four-things-go-right bull case with zero years of positive FCF to support it. Legacy iStent is melting, Epioxa is a Photrexa swap dressed as growth, the Avedro deal was just partially written off, SBC is 12.5% of revenue, insiders have not bought a share in two years at any price, and the stock has already proven it halves when reimbursement fear meets a full multiple. Any of a MAC fee cut, ASP erosion, an Epioxa coverage stall, or a single soft quarter re-runs 2025.

The 3–5 assumptions that matter most:

1. iDose reimbursement durability (J-code + MAC professional fees + ASP hold). Falsified by: a CMS/MAC professional-fee cut, adverse ASP dynamics, or a coverage-policy reversal.
2. iDose adoption keeps compounding through competitive entry. Falsified by: sequential iDose revenue plateauing or decelerating sharply, or Alcon/others taking share with sustained-release entrants.
3. Operating-leverage / path to positive FCF. Falsified by: opex staying ~90%+ of revenue and FCF failing to turn positive by ~FY27.
4. Epioxa becomes a real franchise (coverage → volume), not just a Photrexa cannibalization. Falsified by: corneal revenue declining through 2026–27 as the swap nets negative.
5. The multiple survives. Falsified by: any growth wobble triggering the peer-standard de-rating (BSX/ALGN precedent).

The factor-positioning read (FactorsToday). Glaukos is a crowded momentum trade, not an abandoned value name — +58% trailing 12 months (Sharpe 1.06), +166% annualized over 3 months, 2.7% off its relative-strength peak, with factor-similar peers in the high-growth-momentum cohort (Zscaler, med-device growth ETFs). This is important for variant perception in both directions: momentum names run further than fundamentals justify on the way up (supporting the bulls’ near-term tape), but they also unwind violently when the growth narrative stumbles (supporting the bears’ asymmetry). The tape is not evidence of value; it is evidence that consensus is long and crowded — which is precisely when the risk/reward of a fresh entry is least attractive. The variant-perception edge is therefore less “is the business good?” (it is) and more “is a crowded, richly-priced, reimbursement-dependent momentum name the right thing to buy at the top of its range?” — where the honest answer is not here.

12. Fact vs. Interpretation Table

13. Open Questions

1. iDose net price durability: How do the two remaining unstable MACs (CGS, WPS) resolve their professional fees, and how does iDose ASP behave as volume scales and any competitor enters? This is the single most thesis-relevant unknown.
2. Operating-leverage timing: In which quarter/year does Glaukos cross into sustained positive free cash flow? Management says it is the near-term objective — what is the actual glide path, and does SG&A/revenue keep falling toward peer norms?
3. Epioxa net franchise math: Does Epioxa’s coverage build (post-J2789, 7/1/2026) net positive against Photrexa cannibalization, or does corneal revenue dip through 2026–27 before recovering?
4. DSO / channel loading: Receivables have grown faster than revenue amid iDose “extended payment terms” — is any portion of the reported ramp channel inventory rather than end-demand?
5. iDose re-dosing realization: What percentage of the initial iDose cohort actually returns for re-administration at ~3 years, and at what net price? The annuity thesis lives or dies here — and the first real re-dosing data is still ahead.
6. Governance/succession: What does the Burns (Chairman & CEO) / Gilliam (President & CEO) co-structure signal, and does consistent CEO selling continue?
7. Competitive timeline: When do Alcon or others reach market with a competing sustained-release intracameral therapy, and how much of iDose’s first-mover pricing does that compress?

14. What Must Be True

Bull case — what must be true, and the falsification test.

• iDose continues compounding (multi-year sequential revenue growth) with reimbursement intact. Falsification: two consecutive quarters of decelerating/flat sequential iDose revenue, or a CMS/MAC professional-fee cut or adverse ASP move.
• The cost base operating-levers into sustained positive free cash flow by ~FY27. Falsification: FY26/FY27 FCF still negative with opex stuck at ~90%+ of revenue.
• Epioxa becomes a genuine, coverage-backed franchise that grows the corneal line. Falsification: corneal revenue net-declines through 2026–27 as the Photrexa swap nets negative.
• The re-dosing annuity is real. Falsification: low return-for-re-administration rates as the first iDose cohorts reach ~3 years.

Bear case — what must be true, and the falsification test.

• iDose economics prove reimbursement-fragile (fee/ASP compression) or adoption plateaus. Falsification: iDose keeps compounding and MAC fees/ASP hold for multiple quarters — the moat behaves durably.
• The multiple de-rates on any wobble (peer precedent). Falsification: the stock sustains ~14x+ forward sales through a deceleration — i.e., the market awards durable-compounder credit that survives a soft print.
• Legacy iStent decline turns disorderly and the launches can’t outrun it. Falsification: total glaucoma revenue keeps accelerating with iDose more than offsetting stents (as in FY25) — which it currently is.

Synthesis. The bull and bear cases are not far apart on the business — both agree iDose is good and growing. They diverge almost entirely on (a) reimbursement durability and (b) whether a near-record multiple can survive the inevitable bumps. That is why this is a valuation-and-timing call, not a quality call: the disagreement is about price and fragility, not about whether Glaukos is a real company. It is.

15. Source Appendix

See the separate Source Appendix (Appendix B, below) for the full citation list. Primary sources relied upon:

• SEC filings (CIK 0001192448): FY2025 10-K (filed 2026-02-23); FY2024 10-K (2025-02-25); Q1’26 10-Q (2026-04-30); prior 10-Ks/10-Qs; 8-K corpus (61 filings, 2021–2026); DEF 14A proxies (2022–2025); Form 4 corpus (126 filings, trailing 24 months). Mirrored locally to output/GKOS/sources/.
• Earnings call: Q1’26 (2026-04-29), via ROIC.ai transcript tools; Q4’25, Q3’25 enumerated.
• Quantitative data: ROIC.ai MCP (income statement, balance sheet, cash flow, enterprise value, valuation multiples, profitability ratios); AZI price CSV (5-year OHLCV) and valuation-index own-history percentiles; AZI news feed (Jun–Jul 2026 analyst actions); FactorsToday factor model (loadings, leaderboard, stock-info, related-stocks).
• Reimbursement/industry: CMS/HCPCS coding and Medicare fee-schedule data (iDose J7355, Epioxa J2789, APC 5492, CPT 0660T/0661T/0402T); Grand View Research market sizing (accessed Jul 2026).
• Comparable public companies: Cooper (COO), Edwards (EW), Intuitive Surgical (ISRG), Boston Scientific (BSX), Align (ALGN), and Alcon (ALC) public filings — for peer valuation and moat framing.

No BUY/SELL recommendation and no price target appears anywhere in Sections 1–15; the single labeled exception is the “Claude’s Take” block, which is the author’s own independent opinion. This article is general information, not investment advice.

APPENDIX A — Standard Diligence Questionnaire

Glaukos Corporation (NYSE: GKOS) · Report date 2026-07-18 · Supplemental to the research memo (not counted toward the memo’s length standard). Answers are grounded in the underlying analysis; Fact / Interpretation / Assumption labels applied where they matter.

General

What thoughtful questions have other investors asked about this company? The recurring institutional debates are: (1) Is iDose’s reimbursement durable, or is the ~$14.7k/implant economics a cliff? — resolved on the drug component (permanent J-code J7355) but live on the MAC professional fee (5 of 7 MACs stable). (2) When does Glaukos actually make money? — opex is ~95% of revenue and FCF has never been positive; the whole thesis is a margin-conversion bet. (3) How much of the iStent core is melting? — the Nov-2024 MAC LCDs restricting stacked MIGS flattened legacy stents. (4) What is the real re-dosing rate for iDose? — the ~3-year annuity is central but the first re-dosing cohort data is still ahead. (5) Is the ~14x forward-sales multiple justified for a still-lossmaking company?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Neither — Glaukos is not cyclical; it is a secular launch-ramp story. “Earnings” are negative (GAAP net loss −$187.7M FY25); the relevant question is trajectory, not cycle. Revenue is at an all-time high and accelerating (Fact).

Driven by external environment or internal actions? Overwhelmingly internal — the iDose TR launch and Epioxa introduction are company-specific catalysts. The main external dependency is CMS/MAC reimbursement policy (Fact).

How stable are revenues? Growing and reasonably visible near-term (guidance-backed, procedure-driven), but not contractually recurring. iDose’s ~3-year re-dosing gives an emerging annuity quality; legacy stents are declining (Interpretation).

Outlook for products/services? iDose: multi-year ramp with long runway (underpenetrated interventional glaucoma). Epioxa: TAM-expanding but early. Legacy iStent: flat-to-declining. Pipeline: 5 platforms / 13 programs, mostly free options (Fact/Interpretation).

How big will this market be? Interventional glaucoma is potentially large (millions of non-adherent topical-glaucoma patients, tiny current penetration); MIGS device market modest (~$540M, ~5% CAGR); CXL small (~$290–420M). Growing, primarily US today with international expansion (Fact, market data accessed Jul 2026).

Business Quality & Competitive Moat

Is the industry getting more or less competitive? MIGS is more competitive and reimbursement-pressured (Alcon Hydrus, Sight Sciences, AbbVie XEN). Interventional-pharma (iDose) is first-mover-advantaged today but will attract sustained-release competition (Interpretation).

How profitable is the business (ROIC, ROE)? Not yet profitable — negative ROA (−13% to −20%), no meaningful ROIC/ROE (GAAP losses). Underlying gross margin ~84% adjusted is excellent; the issue is opex intensity, not unit economics (Fact).

How profitable is the industry — competitors, barriers to entry? Barriers are high (multi-year FDA/MDR approval, clinical data, reimbursement coding). Alcon (~55–60% of glaucoma-surgery-device value) is the profit-pool leader; Glaukos is subscale (Fact/approx.).

Can the business be easily understood? Moderately — the products and economics are comprehensible, but the reimbursement mechanics (J-codes, MAC fees, ASP+6%, APC mapping) require specialist knowledge and are the crux of the thesis (Interpretation).

Undermined by foreign low-cost labor? No — this is IP/clinical/regulatory-driven, not labor-cost-driven.

Do brands matter? Modestly — “iStent”/“iDose” carry surgeon mindshare, but purchasing is driven by clinical data, reimbursement, and surgeon relationships, not consumer brand (Interpretation).

Nature of competition? Clinical differentiation, reimbursement pathway, salesforce/surgeon relationships, and IP. Not price-led (yet).

Customers’ switching costs? Weak — a surgeon can switch products procedure-to-procedure; stickiness is habit/training, not lock-in (Interpretation).

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The iDose franchise value and pipeline optionality are internally-generated and not capitalized — genuine off-balance-sheet value if they succeed (Interpretation). Conversely, ~$200M of intangibles + $67M goodwill sit on the balance sheet, and one ($112.9M Photrexa) was just impaired.

Off-balance-sheet liabilities? None material beyond the ~$103M finance/build-to-suit HQ lease (on balance sheet) and routine operating leases. No pension/large contingent liabilities surfaced (Fact).

How conservative is the accounting? Reasonably — the prompt $112.9M Photrexa write-off (rather than dragging out amortization) is a conservative signal. Watch the wide GAAP-vs-adjusted gross-margin gap and SBC add-backs; adjusted metrics flatter the picture and SBC (12.5% of revenue) is a real cost (Interpretation).

How CapEx-hungry? Modestly — FY25 capex ~$24M (~5% of revenue), plus a $16.6M building purchase. The cash drain is opex (SG&A + R&D), not capex (Fact).

Capital Allocation & Management

How much FCF does the business generate; how is it used? None — FCF is negative every year (FY25 −$39M). Cash is consumed by launch spend and R&D, funded by the balance sheet and equity issuance (Fact).

Significant acquisitions recently? Mobius/Mitosol (~$12.4M, 2025) and license deals; the marquee deal remains the 2019 ~$500M all-stock Avedro (Photrexa/CXL), now partially written off (Fact). Capital-allocation verdict: below-average / dilution-financed (Interpretation).

Buying back shares? No — no repurchase program.

Issuing shares to insiders / dilution? Yes — share count +30% over five years (44.5M→58.1M); SBC 12.5% of revenue; 4.25M shares from the 2024 convert exchange (Fact).

Compensation policy / directors’ & management’s motivations? Equity-heavy comp; directors and officers routinely exercise-and-sell (all 10b5-1). CEO Burns is the largest monetizer; zero open-market insider buying in 24 months. Motivation appears growth/pipeline-focused rather than per-share-value-focused (Interpretation).

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — a US C-corp common stock on the NYSE; standard 1099 treatment.

Dividend policy? None — never paid a dividend; no plans to.

How profitable is the business? GAAP-unprofitable today; ~84% adjusted gross margin with improving operating leverage (Q1’26 operating margin −13% vs −19% a year earlier) (Fact).

Is net income diverging from cash from operations? Both are negative; CFO (−$14.8M FY25) is less negative than net income (−$187.7M) because of large non-cash items (the $115.5M impairment, $63.2M SBC, $42.3M D&A). The gap is non-cash charges, not aggressive revenue recognition — though monitor receivables/DSO given iDose “extended payment terms” (Fact/Open Question).

Risks & Downside

What factors would cause the stock to decline? A MAC professional-fee cut or iDose ASP erosion; an Epioxa coverage stall; any growth deceleration triggering multiple de-rating (peer precedent: BSX/ALGN halved); continued cash burn without a path to FCF; disorderly legacy-iStent decline (Interpretation).

Risk of a catastrophic loss? Low — net cash, ~$550M diversified revenue, no going-concern risk.

Chance of a total loss? Very low. The realistic downside is a 30–50% drawdown on de-rating, not a wipeout — the business has genuine catastrophe-resistance; the valuation has genuine drawdown risk (Interpretation).

Recent News & Events

Has the business environment changed recently? Yes, favorably on execution — FY26 guidance raised twice; Epioxa launched (H1 2026) with permanent J-code J2789 effective 7/1/2026; iDose re-administration sNDA approved (Jan 2026); GLK-321 Phase 2 enrollment completed (Jun 2026). Uniformly bullish sell-side (four PT hikes to $150–180 in Jun–Jul 2026) (Fact, AZI news feed).

Significant acquisitions? Mobius/Mitosol (2025); no large deals since Avedro (2019).

Change in accounting policies? No policy change; the $112.9M Photrexa impairment is an estimate/recoverability event, not a policy shift.

Recent changes — new markets, facilities, management? iStent infinite EU launch (late 2025); Aliso Viejo building purchase (2025); co-CEO structure (Burns Chairman & CEO / Gilliam President & CEO); relatively new CFO (Thurman) (Fact).

APPENDIX B — Source Appendix

Glaukos Corporation (NYSE: GKOS) · Report date 2026-07-18. Primary sources over secondary; each material claim in the article traces to a documented source. Facts are labeled in the body; this appendix lists what was relied upon.

1. SEC filings (primary; CIK 0001192448) — mirrored locally to output/GKOS/sources/

2. Earnings call transcripts (primary)

• Q1’26 earnings call — 2026-04-29 (via ROIC.ai transcript tools). FY26 guidance raise to $620–635M; iDose ~$54M in Q1; franchise splits; Epioxa launch & J-code J2789; reimbursement (5 of 7 MACs stable); co-CEO commentary; cash-flow-breakeven objective.
• Q4’25 (2026-02-17) and Q3’25 (2025-10-30) — enumerated for context.

3. Quantitative data sources (third-party aggregated; reconciled to filings)

• ROIC.ai MCP — income statement, balance sheet, cash flow (annual + quarterly, FY19–Q1’26); enterprise value; valuation multiples; profitability ratios; per-share data. Primary computed-ratio source, reconciled to EDGAR.
• Market price & valuation-percentile data — 5-year daily price/OHLCV CSV (event-map price levels, EMAs, beta/alpha); valuation-index own-history percentile ranks (P/S 89th pct, P/B 90th pct, composite 89.6th pct); news feed (Jun–Jul 2026 analyst actions & pipeline items).
• FactorsToday — factor loadings, leaderboard (risk-adjusted returns by horizon), stock-info (beta/alpha/relative strength), related-stocks (factor-similar peers). Positioning/momentum read.

4. Reimbursement & industry data

• CMS / HCPCS coding & Medicare fee schedules (accessed Jul 2026): iDose drug code J7355 (permanent, eff. 7/1/2024; ~$195.72/unit × 75 units ≈ $14,679/implant); procedure CPT 0660T/0661T → facility APC 5492; Epioxa J2789 (eff. 7/1/2026) and interim CPT 0402T; Nov-2024 MAC LCDs on combined/stacked MIGS.
• Grand View Research and related market sizing (accessed Jul 2026): MIGS device market (~$540M, ~5% CAGR); glaucoma-surgery-device market (~$1.8B); CXL device market (~$290–420M); keratoconus prevalence (~54.5/100,000).

5. Analyst actions (secondary; signal only, validated against primaries)

• June–July 2026 sell-side updates (via AZI news feed): BTIG, Citigroup, Needham, Piper Sandler, HC Wainwright (initiation), Truist, Stifel — price targets clustering $150–180. Used only to characterize consensus/momentum, not as valuation evidence.

6. Comparable public companies (cross-read)

• Public filings and market data for Cooper Companies (COO), Edwards Lifesciences (EW), Intuitive Surgical (ISRG), Boston Scientific (BSX), and Align Technology (ALGN) — peer valuation multiples, moat frameworks, and de-rating precedents for the valuation and variant-perception sections.
• Alcon (ALC) public disclosures and financial data — ophthalmic-surgical industry structure, competitive positioning, and share/quantitative benchmarks. Sight Sciences (SGHT) and other competitor public filings for competitive context.

Where a third-party data source and a filing disagree on a material number, the filing governs. Third-party estimates are labeled as such; management commentary is treated as hypothesis and validated against filings and external data.